• Featured Product
  • KD/KO Validated

PD-L1/CD274 Polyclonal antibody

PD-L1/CD274 Polyclonal Antibody for FC, IF, IHC, IP, WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IP, IHC, IF, FC, CoIP, ChIP, ELISA

Conjugate

Unconjugated

Cat no : 17952-1-AP

Synonyms

PD-L1/CD274



Tested Applications

Positive WB detected inhuman placenta tissue, mouse heart tissue, HepG2 cells, K-562 cells, IFN gamma treated A549 cells, A375 cells, human heart tissue, HeLa cells, mouse skeletal muscle tissue
Positive IP detected inmouse heart tissue
Positive IHC detected inhuman tonsillitis tissue, mouse heart tissue, human stomach cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHEK-293 cells
Positive FC detected inRaji cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:500-1:2000 for WB
Immunohistochemistry (IHC)IHC : 1:300-1:1200
Immunofluorescence (IF)IF : 1:10-1:100
Sample-dependent, check data in validation data gallery

Product Information

17952-1-AP targets PD-L1/CD274 in WB, IP, IHC, IF, FC, CoIP, ChIP, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen PD-L1/CD274 fusion protein Ag12432
Full Name CD274 molecule
Calculated molecular weight 290 aa, 33 kDa
Observed molecular weight 45-56 kDa, 65-70 kDa
GenBank accession numberBC074984
Gene symbol CD274
Gene ID (NCBI) 29126
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. 

What is the molecular weight of PD-L1? 

Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa). 

What are the isoforms of PD-L1? 

According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions. 

What is the subcellular localization and tissue specificity of PD-L1? 

It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues. 

What is the function of PD-L1 in immune responses? 

PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681). 

How can PD-L1's implication in cancer be used as a drug target? 

In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).


Protocols

Product Specific Protocols
WB protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
IHC protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
IF protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
IP protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
FC protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Nat Biomed Eng

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.

Authors - Han Yao
humanWB,IHC,IF

Mol Cell

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Authors - Xin Jin
mouseIHC,IF

Nat Commun

IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.

Authors - Shao-Wei Lu
humanWB

Nat Commun

WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.

Authors - Man Wu
mouse,humanIHC,IF

Nat Commun

TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.

Authors - Yimeng Ren
humanIHC,WB

Cell Death Differ

KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.

Authors - Wenwen Du
  • KD Validated